MassBio’s 2018 Industry Snapshot – Boston/Cambridge Leads the Way

Home/Financial, Spotlights/MassBio’s 2018 Industry Snapshot – Boston/Cambridge Leads the Way

MassBio’s 2018 Industry Snapshot – Boston/Cambridge Leads the Way

Introduction of press release from MassBio:

“August 29 – The Massachusetts Biotechnology Council (MassBio) released its 2018 Industry Snapshot report, which shows that Massachusetts biotechs dominated the IPO market in 2017, accounting for nearly half of all US-based biotech IPOs (48%), up from 30% in 2016. 2018 has already outpaced 2017 in terms of total Massachusetts IPOs at 15, which accounts for nearly 40% of all US-based biotech IPOs (January – July 2018). The industry’s success is also expanding across the Commonwealth, with half of the 2017 Massachusetts-based IPOs occurring in biotechs outside of Cambridge in places like Waltham, Newton and Burlington.

When looking at the investment side, it’s a similar story. In 2017, venture capital investment in Massachusetts biopharma companies was $3.1 billion, the highest ever, which accounts for 37% of all US biopharma VC dollars. In just the first two quarters of 2018, VC investments in Massachusetts biopharmas has nearly reached 2017 totals, with $2.7 billion invested. The average deal size has also increased dramatically year-over-year, going from $34 million in 2017 to $51 million in the first two quarters of 2018.”

Full press release

ADDITIONAL COVERAGE:

  • The booming Boston/Cambridge biotech hub claims an industry-leading role — nobody beats it at raising record amounts of money (Endpoints)
  • The IPO boom has been particularly kind to biotech in Massachusetts (STAT)
  • Massachusetts Biopharma Shows Workforce, Investment Growth (GEN)
  • Will 2018 Set a Record for Biotech IPOs? (Boston Globe)
September 3rd, 2018|
X